Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024
Vaxart (VXRT) announced its participation in the World Vaccine Congress Europe 2024 in Barcelona, where it will present research on its COVID-19 and norovirus oral pill vaccine candidates. The company will deliver two presentations: a clinical update on their oral COVID vaccine's Phase 1 to Phase 2B trials by CMO Dr. James F. Cummings, and research on their oral norovirus vaccine's cross-reactivity and protection against infection by CSO Dr. Sean Tucker. Vaxart's platform has shown both systemic and mucosal immune responses with favorable safety profiles in clinical trials.
Vaxart (VXRT) ha annunciato la sua partecipazione al World Vaccine Congress Europe 2024 a Barcellona, dove presenterà ricerche sui suoi candidati vaccinali orali per COVID-19 e norovirus. L'azienda terrà due presentazioni: un aggiornamento clinico sui trial di Fase 1 e Fase 2B del vaccino orale contro il COVID, presentato dal CMO Dr. James F. Cummings, e una ricerca sulla reattività incrociata e protezione contro l'infezione del vaccino orale contro il norovirus, condotta dal CSO Dr. Sean Tucker. La piattaforma di Vaxart ha mostrato risposte immunitarie sia sistemiche che mucosali con profili di sicurezza favorevoli nei trial clinici.
Vaxart (VXRT) anunció su participación en el World Vaccine Congress Europe 2024 en Barcelona, donde presentará investigaciones sobre sus candidatos a vacunas orales para COVID-19 y norovirus. La compañía realizará dos presentaciones: una actualización clínica sobre los ensayos de Fase 1 a Fase 2B de su vacuna oral contra COVID a cargo del CMO Dr. James F. Cummings, y una investigación sobre la reactividad cruzada de su vacuna oral contra el norovirus y la protección contra la infección presentada por el CSO Dr. Sean Tucker. La plataforma de Vaxart ha mostrado respuestas inmunitarias sistémicas y mucosales con perfiles de seguridad favorables en ensayos clínicos.
Vaxart (VXRT)는 2024 유럽 세계 백신 회의에 참가할 것이라고 발표하였으며, 바르셀로나에서 COVID-19 및 노로바이러스 경구 백신 후보에 대한 연구 결과를 발표할 예정이다. 이 회사는 두 개의 발표를 진행할 예정이며, CMO Dr. James F. Cummings가 경구 COVID 백신의 1상에서 2B상 임상 시험에 대한 임상 업데이트를 발표하고, CSO Dr. Sean Tucker가 경구 노로바이러스 백신의 교차 반응성과 감염에 대한 보호 연구를 진행할 것이다. Vaxart의 플랫폼은 임상 시험에서 안전성이 우수한 시스템 면역 반응과 점막 면역 반응을 모두 보였다.
Vaxart (VXRT) a annoncé sa participation au World Vaccine Congress Europe 2024 à Barcelone, où elle présentera des recherches sur ses candidats vaccins oraux contre la COVID-19 et le norovirus. La société fera deux présentations : une mise à jour clinique sur les essais de phase 1 à 2B de son vaccin oral contre la COVID par le CMO Dr. James F. Cummings, et une recherche sur la réactivité croisée et la protection contre l'infection de son vaccin oral contre le norovirus par le CSO Dr. Sean Tucker. La plateforme de Vaxart a montré à la fois des réponses immunitaires systémiques et muqueuses avec des profils de sécurité favorables lors des essais cliniques.
Vaxart (VXRT) hat seine Teilnahme am World Vaccine Congress Europe 2024 in Barcelona angekündigt, wo es Forschungsarbeiten zu seinen oralen Impfstoffkandidaten gegen COVID-19 und Noroviren präsentieren wird. Das Unternehmen wird zwei Präsentationen halten: ein klinisches Update zu den klinischen Studien der Phasen 1 bis 2B des oralen COVID-Impfstoffs durch CMO Dr. James F. Cummings und eine Forschung über die Kreuzreaktivität und den Schutz vor Infektionen des oralen Norovirus-Impfstoffs durch CSO Dr. Sean Tucker. Die Plattform von Vaxart hat sowohl systemische als auch mukosale Immunantworten mit günstigen Sicherheitsprofilen in klinischen Studien gezeigt.
- Platform demonstrates both systemic and mucosal immune responses
- Favorable safety and tolerability profile in clinical trials
- Multiple clinical-stage programs in development
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it will present research featuring its COVID-19 and norovirus oral pill vaccine candidates at the World Vaccine Congress Europe 2024 taking place in Barcelona, Spain on October 28-31, 2024.
Vaxart’s mission is to improve global public health by developing a transformative oral tablet vaccine platform. With multiple promising clinical-stage programs, including those targeting COVID-19 and norovirus, the Company is committed in solving serious health challenges facing society. Vaxart’s differentiated platform has generated both systemic and mucosal immune responses and demonstrated a favorable safety and tolerability profile in clinical trials, reinforcing its potential of bringing worldwide game changing solutions.
Presentation Information:
Title: Oral Covid Vaccine - Clinical Update from Phase 1 to Phase 2B
Speaker: Dr. James F. Cummings, Chief Medical Officer
Date: Tuesday, October 29
Time: 3:55 p.m. CET
Location: Theatre 3
Title: Oral Norovirus Vaccine Induces Cross-reactivity and Protection Against Infection in Humans
Speaker: Dr. Sean Tucker, Founder and Chief Scientific Officer
Date: Wednesday, October 30
Time: 11:40 a.m. CET
Location: Theatre 5
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and to eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations
Matt Steinberg
FINN Partners
IR@vaxart.com
(646) 871-8481
FAQ
What will Vaxart (VXRT) present at the World Vaccine Congress Europe 2024?
When will Vaxart (VXRT) present at the World Vaccine Congress Europe 2024?
What are the key features of Vaxart's (VXRT) vaccine platform?
